Immunovant, Inc. (IMVT) income statement
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$31.77−0.75 (-2.31%)
Close on Nov 20, 2026Market cap $6.56BP/E –Yield –
Immunovant, Inc. financial ratios
See a number that looks wrong?